Cover Image
市場調查報告書

呼吸疾病用吸入器的全球市場 (2017-2027年):各產品類型 (MDI、DPI、噴霧器)、適應症 (氣喘、COPD)、地區

The Global Respiratory Inhalers Market 2017-2027: Revenue Prospects By Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography

出版商 Visiongain Ltd 商品編碼 499466
出版日期 內容資訊 英文 181 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
呼吸疾病用吸入器的全球市場 (2017-2027年):各產品類型 (MDI、DPI、噴霧器)、適應症 (氣喘、COPD)、地區 The Global Respiratory Inhalers Market 2017-2027: Revenue Prospects By Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography
出版日期: 2017年03月21日 內容資訊: 英文 181 Pages
簡介

2017年的全球呼吸疾病用吸入器的收益規模估計超過332億美元,該收益規模預計2027年將更擴大。

本報告提供全球呼吸疾病用吸入器的市場調查,市場及產品定義和概要,呼吸系統疾病 (氣喘、COPD) 和治療概要,主要藥物類別,收益規模的變化與預測,各產品類型、適應症、主要國家的詳細分析,影響市場成長因素及市場機會分析,主要企業簡介,未來展望等彙整資料。

第1章 報告概要

第2章 簡介:呼吸系統疾病和治療

  • 簡介:呼吸系統疾病
    • 呼吸系統疾病的分類
    • 氣喘
      • 盛行率
      • 病理生理學
      • 症狀
      • 治療
      • 指南
      • 藥物治療
    • 慢性阻塞性肺病 (COPD)
      • 趨勢
      • 病理生理學
      • 症狀
      • 治療
      • 藥物治療
      • 指南
  • 氣喘、COPD的主要藥物類別
    • 支氣管擴張劑
      • β2促效劑
      • 抗膽鹼 (作用) 藥
      • 抗發炎藥
      • 皮質類固醇劑 (ICS)
      • 白三烯素受體拮抗劑
      • 單株抗體
      • 組合藥物
    • 臨床試驗的階段
    • 醫療設備相關法律

第3章 全球市場的變化與預測

  • 市場成果
  • 主要產品
  • 主要企業
  • 各種趨勢、發展情形

第4章 市場分析:各產品類型

  • 定量噴霧吸入器 (MDI):市場概要
  • 乾粉吸入劑 (DPI):市場概要
    • 單劑量型
    • 多劑量型
  • 噴霧器:市場概要
    • 噴氣式飛機/壓縮機式
    • 超音波噴霧器
    • 篩孔式噴霧器

第5章 市場分析:各適應症

  • 氣喘:市場概要
  • COPD:市場概要
  • 其他呼吸系統疾病

第6章 主要國家市場預測

  • 全球市場:各地區明細
  • 全球市場的變化與預測
  • 美國
    • 市場規模的變化與預測
    • 各種趨勢、發展情形
  • 歐盟5國
    • 市場規模的變化與預測
    • 各種趨勢、發展情形
      • 德國
      • 法國
      • 英國
      • 義大利
      • 西班牙
  • 日本
    • 市場規模的變化與預測
    • 各種趨勢、發展情形
  • 金磚四國
    • 市場規模的變化與預測
      • 中國
      • 印度
      • 巴西
      • 俄羅斯
  • 墨西哥

第7章 主要企業

  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Boehringer Ingelheim
  • Merck & Co. (Merck)
  • Teva
  • Novartis International AG
  • Chiesi Farmaceutici S.p.A.
    • 產品系列
    • 財務概要
    • 近幾年的發展情形等

第8章 定性分析

  • 市場動態
    • 成長推動因素、市場機會
    • 阻礙成長要素、課題
  • 波特的五力分析

第9章 總論

第10章 用語

目錄
Product Code: PHA0177

Respiratory Inhalers - our new study reveals trends, R&D progress, and predicted revenues

Where is the Respiratory Inhalers market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 181-page report provides 118 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Respiratory Inhalers market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, 8 Products and 3 indications are also forecasted.

Respiratory Inhalers Market Forecasts to 2027, by Product:

  • Metered Dose Inhalers
  • Dry Powder Inhalers
    • Single-Dose DPIs
    • Multi-Dose DPIs
  • Nebulizers
    • Jet / Compressor Nebulizers
    • Ultrasonic Nebulizers
    • Vibrating-Mesh Nebulizers

Respiratory Inhalers Market Forecasts to 2027, by Application:

  • Asthma
  • COPD
  • Other Respiratory Diseases

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 12 leading national markets:

  • The US
  • The EU5 markets
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • Japan
  • China
  • India
  • Russia
  • Brazil
  • Mexico

The report also includes profiles and forecasts for some of the leading companies in the Respiratory Inhalers device market, with a focus on the Respiratory Inhalers device segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.

Leading companies and the potential for market growth

Overall world revenue for Respiratory Inhalers will surpass $33.2bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing use of Respiratory Inhalers across many types of surgery and increasing ageing population will increase sales to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Respiratory Inhalers Market report helps you

In summary, our 181-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the world Respiratory Inhalers market and 2 different segmentations, with 8 product types and 3 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 12 of the leading national markets - US, Mexico, Brazil, Germany, UK, France, Italy, Spain, Japan, China, India, the Rest of World markets.
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Respiratory Inhalers device market and leading companies. You find data, trends and predictions.

Get our report today The Global Respiratory Inhalers Market 2017-2027: Revenue Prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), by Indication (Asthma and COPD) and Geography. Avoid missing out - get our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Respiratory Inhalers Market Overview
  • 1.2. Global Respiratory Inhalers Market Segmentation
  • 1.3. Overview of Findings
  • 1.4. Structure of the Report
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
    • 1.9.1. Primary Research
    • 1.9.2. Secondary Research
    • 1.9.3. Market Evaluation & Forecasting Methodology
  • 1.10. Frequently Asked Questions (FAQ)
  • 1.11. Associated Visiongain Reports
  • 1.12. About Visiongain

2. Introduction to Respiratory Disorders and Therapies

  • 2.1. An Introduction to Respiratory Disorders
    • 2.1.1. Classification of Respiratory Disorders
    • 2.1.2. Asthma
      • 2.1.2.1. Trends in Asthma Prevalence
      • 2.1.2.2. Pathophysiology of Asthma
      • 2.1.2.3. Symptoms of Asthma
      • 2.1.2.4. Treatment of Asthma
      • 2.1.2.5. Guidelines for Asthma Treatment
      • 2.1.2.6. Drug Treatments for Asthma
    • 2.1.3. Chronic Obstructive Pulmonary Disease (COPD)
      • 2.1.3.1. Trends in COPD Prevalence
      • 2.1.3.2. Pathophysiology of COPD
      • 2.1.3.3. Symptoms of COPD
      • 2.1.3.4. Treatment of COPD
      • 2.1.3.5. Drug Treatments for COPD
      • 2.1.3.6. Guidelines for COPD Treatment
  • 2.2. Major Drug Classes in the Treatment of Asthma and COPD
    • 2.2.1. Bronchodilators
      • 2.2.1.1. Beta2-Agonists
      • 2.2.1.2. Anticholinergics
      • 2.2.1.3. Anti-Inflammatory Drugs
      • 2.2.1.4. Corticosteroids
      • 2.2.1.5. Leukotriene Receptor Antagonists
      • 2.2.1.6. Monoclonal Antibodies in the Treatment of Respiratory Disease
      • 2.2.1.7. Combination Drugs
    • 2.2.2. Phases of Clinical Trials
    • 2.2.3. Regulation of Medical Devices
      • 2.2.3.1. The US Approval and Regulation System
      • 2.2.3.2. The EU Approval and Regulation System
      • 2.2.3.3. Post-Marketing Surveillance in the EU

3. Respiratory Inhalers: Global Market 2016-2027

  • 3.1. The Global Respiratory Inhalers Market in 2016
  • 3.2. Leading Respiratory Inhaler Products
  • 3.3. Leading Companies in the Respiratory Inhalers Market
  • 3.4. Respiratory Inhalers: Trends and Developments
    • 3.4.1. FDA Requires Replacement of CFC Inhalers with HFA Inhalers
    • 3.4.2. The WISDOM Trial: Will Steroids Lose Their Role in COPD?
    • 3.4.3. Telehealth: A Promising Market Trend
    • 3.4.4. Lifecycle Management Strategies to Counter Patent Expiry
    • 3.4.5. Advanced Inhaler Technologies to Counter Generic Erosion

4. Respiratory Inhalers Market, By Product Type

  • 4.1. Metered Dose Inhalers: Market Overview
  • 4.2. Dry Powder Inhalers: Market Overview
    • 4.2.1. Single-Dose DPIs
    • 4.2.2. Multi-Dose DPIs
  • 4.3. Nebulizers: Market Overview
    • 4.3.1. Jet/Compressor Nebulizers
    • 4.3.2. Ultrasonic Nebulizers
    • 4.3.3. Vibrating-Mesh Nebulizers

5. Respiratory Inhalers Market, by Indication

  • 5.1. Asthma: Market Overview
  • 5.2. COPD: Market Overview
  • 5.3. Other Respiratory Diseases

6. Leading National Markets 2016-2027

  • 6.1. Regional Breakdown of the Global Respiratory Inhalers Market
  • 6.2. World Respiratory Inhalers Market Forecast 2016-2027
    • 6.2.1. How will Regional Market Shares Change to 2027?
  • 6.3. The US Respiratory Inhalers Market 2016-2027
    • 6.3.1. The US Respiratory Inhalers Market Forecast 2016-2027
    • 6.3.2. US Respiratory Inhalers Market: Trends and Developments
  • 6.4. EU5 Respiratory Inhalers Market 2016-2027
    • 6.4.1. German Respiratory Inhalers Market Forecast 2016-2027
    • 6.4.2. French Respiratory Inhalers Market Forecast 2016-2027
    • 6.4.3. UK Respiratory Inhalers Market Forecast 2017-2027
    • 6.4.4. Italian Respiratory Inhalers Market Forecast 2017-2027
    • 6.4.5. Spanish Respiratory Inhalers Market Forecast 2017-2027
    • 6.4.6. EU5 Respiratory Inhalers Market: Trends and Developments
      • 6.4.6.1. Germany: Reform of AMNOG Pharmaceutical Rebate Law
      • 6.4.6.2. France: Social Security Finance Bill 2015
      • 6.4.6.3. UK: Improving Asthma and COPD Patient Outcomes
      • 6.4.6.4. Italy: Austerity Measures Limiting Growth
      • 6.4.6.5. Spain: The Start of Recovery in the Spanish Economy
  • 6.5. Japanese Respiratory Inhalers Market 2016-2027
  • 6.6. BRIC Respiratory Inhalers Market 2016-2027
    • 6.6.1. Chinese Respiratory Inhalers Market Forecast 2016-2027
    • 6.6.2. Indian Respiratory Inhalers Market Forecast 2016-2027
    • 6.6.3. Brazilian Respiratory Inhalers Market Forecast 2016-2027
    • 6.6.4. Russian Respiratory Inhalers Market Forecast 2016-2027
  • 6.7. Mexican Respiratory Inhalers Market Forecast 2016-2027

7. Leading Companies in the Respiratory Inhalers Market

  • 7.1. GlaxoSmithKline (GSK)
    • 7.1.1. GSK: Product Portfolio
    • 7.1.2. GSK: Financial Overview
    • 7.1.3. Recent Developments
      • 7.1.3.1. Japanese Regulatory Approval for Relvar Ellipta
      • 7.1.3.2. FDA Filing of Triple Drug Therapy
      • 7.1.3.3. FDA Approval for Breo Ellipta to Adult Asthma Patients
      • 7.1.3.4. Launch of Combination Drugs
      • 7.1.3.5. GSK Presented Data on Eosinophil Levels and COPD
      • 7.1.3.6. Approval for Arnuity Ellipta
      • 7.1.3.7. Approval for Incruse Ellipta
      • 7.1.3.8. GSK: Products in Development
  • 7.2. AstraZeneca
    • 7.2.1. AstraZeneca: Product Portfolio
    • 7.2.2. AstraZeneca: Financial Overview
    • 7.2.3. Recent Developments
      • 7.2.3.1. FDA Approval for Symbicort in Paediatric Patients
      • 7.2.3.2. Charity-Industry Collaboration
      • 7.2.3.3. FDA approval for Bevespi Aerosphere
      • 7.2.3.4. AstraZeneca Acquired Right to Actavis' Branded Respiratory Portfolio in US and Canada
      • 7.2.3.5. AstraZeneca Acquired Almirall's Respiratory Portfolio
      • 7.2.3.6. Takeda Respiratory Portfolio Acquisition
    • 7.2.4. AstraZeneca: Products in Development
  • 7.3. Boehringer Ingelheim
    • 7.3.1. Boehringer Ingelheim: Product Portfolio
    • 7.3.2. Boehringer Ingelheim: Financial Overview
    • 7.3.3. Recent Developments
      • 7.3.3.1. Collaboration with Kaohsiung Medical University
      • 7.3.3.2. Collaboration with Weill Cornell Medicine
      • 7.3.3.3. Collaboration with Qualcomm Incorporated
      • 7.3.3.4. Partnership with Propeller Health
      • 7.3.3.5. FDA Approval for Spiriva Respimat
      • 7.3.3.6. Regulatory Approval for Stiolto Respimat
      • 7.3.3.7. Expansion of Respimat Manufacturing Capacity
      • 7.3.3.8. FDA Approval for Stiverdi Respimat
    • 7.3.4. Boehringer Ingelheim: Respiratory Product Pipeline
  • 7.4. Merck & Co. (Merck)
    • 7.4.1. Merck: Product Portfolio
    • 7.4.2. Merck: Financial Overview
    • 7.4.3. Recent Developments
    • 7.4.4. Merck: Products in Development
  • 7.5. Teva
    • 7.5.1. Teva: Product Portfolio
    • 7.5.2. Teva: Financial Overview
    • 7.5.3. Teva: Recent Developments
      • 7.5.3.1. FDA Approval for RespiClick
      • 7.5.3.2. European Approval for Aerivio Spiromax
      • 7.5.3.3. FDA Approval for ProAir RespiClick (albuterol sulfate)
      • 7.5.3.4. Acquisition of Gecko Health Innovations
      • 7.5.3.5. Partnership with IBM Watson Health
    • 7.5.4. Teva: Products in Development
  • 7.6. Novartis International AG
    • 7.6.1. Novartis: Product Portfolio
    • 7.6.2. Novartis: Financial Overview
    • 7.6.3. Novartis: Recent Developments
      • 7.6.3.1. Partnership with Propeller Health
      • 7.6.3.2. Exclusive License Agreement with Sunovion Pharma
      • 7.6.3.3. Partnership with Qualcomm Incorporated
      • 7.6.3.4. FDA Approval for Utibron Neohaler
      • 7.6.3.5. Novartis Presented Data on Ultibro and Seebri
      • 7.6.3.6. Pfizer Promotes Two Novartis COPD drugs in the UK
    • 7.6.4. Novartis: Products Under Development
  • 7.7. Chiesi Farmaceutici S.p.A.
    • 7.7.1. Chiesi: Product Portfolio
    • 7.7.2. Chiesi: Financial Overview
    • 7.7.3. Chiesi: Recent Developments
      • 7.7.3.1. Regulatory Approval for NEXThaler
      • 7.7.3.2. Chiesi: Products Under Development

8. Qualitative Analysis of Respiratory Inhalers Market

  • 8.1. Market Dynamics
    • 8.1.1. Drivers and Opportunities
      • 8.1.1.1. Growing Burden of Respiratory Diseases
      • 8.1.1.2. Smart Inhalers Provide High Growth Opportunities
      • 8.1.1.3. Triple Drug Therapy for COPD To Offer New Revenue Prospects
    • 8.1.2. Restraints and Challenges
      • 8.1.2.1. Patent Expiry and Generic Competition
      • 8.1.2.2. High Cost Impeding Growth of DPIs In Cost-Sensitive Markets
  • 8.2. Porter's Five Forces Analysis of the Respiratory Inhalers Market
    • 8.2.1. Rivalry among Competitors [Medium]
    • 8.2.2. Threat of New Entrants [Medium]
    • 8.2.3. Power of Suppliers [Medium]
    • 8.2.4. Power of Buyers [High]
    • 8.2.5. Threat of Substitutes [Low]

9. Conclusions

  • 9.1. Respiratory Inhalers: A Maturing Market
  • 9.2. The Global Respiratory Inhalers Market, 2016-2027
  • 9.3. Leading Respiratory Inhalers
  • 9.4. Leading Respiratory Inhaler Companies
  • 9.5. Leading Regional and National Markets
  • 9.6. Global Respiratory Inhalers Market Forecast, 2017-2027
  • 9.7. The Future of Respiratory Inhalers Market

10. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Ageing Population Estimates 2010 - 2050
  • Figure 1.2: Global Respiratory Inhalers: Market Segmentation
  • Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
  • Figure 2.2: Summary of GOLD Guidance for COPD Treatment
  • Figure 3.1: World Respiratory Inhalers Market: Market Shares (%) for Major National Markets
  • Figure 3.2: Top 5 Respiratory Inhalers: Market Shares (%), 2016
  • Figure 4.1: Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
  • Figure 4.2: Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.3: World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
  • Figure 4.4: Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.5: Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.6: Jet Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.7: Ultrasonic Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 4.8: Vibrating-mesh Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.1: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027
  • Figure 5.2: World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.3: World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 5.4: World Other Respiratory Diseases Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.1: Respiratory Inhalers Market: Revenues ($m) by Region, 2016
  • Figure 6.2: World Respiratory Inhalers Market: Market Shares (%) by Region, 2016
  • Figure 6.3: World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2027
  • Figure 6.4: World Respiratory Inhalers Market: Market Shares (%) by Region, 2016
  • Figure 6.5: World Respiratory Inhalers Market: Market Shares (%) by Region, 2022
  • Figure 6.6: World Respiratory Inhalers Market: Market Shares (%) by Region, 2027
  • Figure 6.7: US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.8: EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2027
  • Figure 6.9: German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.10: French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.11: UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 6.12: Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.13: Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.14: Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.15: BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.16: Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.17: Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.18: Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.19: Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 6.20: Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027
  • Figure 7.1: GSK: Major Respiratory Inhalers Revenue ($m), 2016
  • Figure 7.2: GSK: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
  • Figure 7.3: GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.4: AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2016
  • Figure 7.5: AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
  • Figure 7.6: AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.7: Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2016
  • Figure 7.8: Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
  • Figure 7.9: Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.10: Merck: Major Respiratory Inhalers Revenue ($m), 2016
  • Figure 7.11: Merck: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
  • Figure 7.12: Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.13: Teva: Major Respiratory Inhalers Revenue ($m), 2016
  • Figure 7.14: Teva: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
  • Figure 7.15: Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.16: Novartis: Major Respiratory Inhalers Revenue ($m), 2016
  • Figure 7.17: Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2016
  • Figure 7.18: Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027
  • Figure 7.19: Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2027
  • Figure 8.1: Porter's Five Forces Analysis of the Respiratory Inhalers Market, 2016-2027
  • Figure 9.1: Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027

List of Tables

  • Table 1.1: Respiratory Inhalers Market Forecast Segmented by National Markets: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 2.1: Classification of Respiratory Diseases
  • Table 2.2: Clinical Trial Phases
  • Table 3.1: Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016
  • Table 4.1: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Product Type, 2016-2027
  • Table 4.2: World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3: World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
  • Table 4.4: Types of Marketed Breezhaler Device
  • Table 4.5: Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6: Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.7: World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Type, 2016-2027
  • Table 4.8: World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10: World Vibrating-mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027
  • Table 5.2: World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.3: World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 5.4: World Other Diseases Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1: World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2016
  • Table 6.2: World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2027
  • Table 6.3: Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027
  • Table 6.4: US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.5: EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027
  • Table 6.6: German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.7: French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8: UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.9: Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.10: Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.11: Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.12: BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.13: Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.14: Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.15: Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.16: Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 6.17: Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1: GSK: Overview, 2016
  • Table 7.2: GSK: Respiratory Inhaler Products
  • Table 7.3: GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%), By Product Type, 2016-2027
  • Table 7.4: GSK: Respiratory Therapies Pipeline, 2016
  • Table 7.5: AstraZeneca: Overview, 2016
  • Table 7.6: AstraZeneca: Respiratory Inhaler Products
  • Table 7.7: AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
  • Table 7.8: AstraZeneca: Respiratory Therapies Pipeline, 2016
  • Table 7.9: Boehringer Ingelheim: Overview, 2016
  • Table 7.10: Boehringer Ingelheim: Respiratory Inhaler Products
  • Table 7.11: Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027
  • Table 7.12: Merck: Overview, 2016
  • Table 7.13: Merck: Respiratory Inhaler Products
  • Table 7.14: Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
  • Table 7.15: Teva: Overview, 2016
  • Table 7.16: Teva: Respiratory Inhaler Products
  • Table 7.17: Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
  • Table 7.18: Teva: Respiratory Product Pipeline, 2016
  • Table 7.19: Novartis: Overview, 2016
  • Table 7.20: Novartis: Respiratory Inhaler Products
  • Table 7.21: Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
  • Table 7.22: Novartis: Respiratory Product Pipeline, 2016
  • Table 7.23: Chiesi: Overview, 2016
  • Table 7.24: Chiesi: Respiratory Inhaler Products
  • Table 7.25: Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027
  • Table 9.1: Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016

Companies Listed

  • 3M Drug Delivery Systems
  • Actavis
  • Adherium Limited
  • Aerogen
  • Agilent Technology
  • Airssential
  • Allied Healthcare
  • Almirall
  • Astrazeneca
  • Boehringer Ingelheim
  • Briggs Healthcare
  • CareFusion
  • Chiesi
  • Cipla
  • Clement Clarke International
  • Cohero Health
  • DeVilbiss Healthcare
  • Fexicare
  • Gecko Health Innovations
  • GF Health Products
  • GlaxoSmithKline
  • Heyer Medical
  • Hikma
  • Innovate Biomed
  • Inspiro Medical
  • Medline Surgical
  • Merck
  • MRK Healthcare
  • Mylan
  • Nexus 6
  • Nouvag AG
  • Novartis
  • Omron Healthcare
  • Opko Health
  • Orion Pharma
  • PARI Medical
  • Pfizer
  • Philips Respironics
  • Propeller Health
  • Qualcomm Incorporated
  • Roche
  • Schering-Plough
  • Sunovion Pharma
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Vectura
  • Viatris

Organizations/Associations Mentioned in the Report

  • British Lung Foundation
  • Centers for Disease Control and Prevention
  • Centre for Devices and Radiological Health
  • European Databank on Medical Devices
  • European Medicines Agency
  • European Respiratory Society
  • Food and Drug Administration
  • German Ministry of Health
  • Global Initiative for Asthma
  • Global Initiative for Chronic Obstructive Lung Disease
  • IBM Watson Health
  • Kaohsiung Medical University
  • Ministry of Health, Labour and Welfare
  • Mount Sinai Hospital
  • MRC Technology
  • ServicioSanitarioNazionale
  • UK NHS
  • US National Heart, Lung, and Blood Institute
  • US National Institutes of Health
  • Weill Cornell Medicine
  • World Health Organization (WHO)
Back to Top